Shenzhen Raysight Medical completed a $46 million Series B funding for its smart systems that offer real-time monitoring to provide early warnings of heart disease. Raysight said it would use the proceeds to perfect its cardiovascular and cerebrovascular closed-loop platform that includes large-scale screening, precision diagnosis, preoperative and intraoperative guidance, and postoperative chronic disease management. The company's first product is a novel wearable non-invasive coronary blood supply evaluation system -- Ruixin-FFR. The B round was led by Tencent with participation from Matrix Partners China. More details.... Share this with colleagues: // //